The proposal calls for banks to make their compliance programs "risk-based" and pledges to emphasize "systemic" flaws with ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What ...

The company said the independent safety board reviewing the study saw a clear trend favoring the Annamycin combination, though there was no statistical significance. ・Full data from the first part of ...

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control ...

Close to a third of firms inspected by the Solicitors Regulation Authority (SRA) were found non-compliant. AMLCC’s Richard Simms explains what inspectors look for and how to ensure your firm is ready.

As a staff writer for Forbes Advisor, SMB, Kristy helps small business owners find the tools they need to keep their ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. The combination of decitabine-cedazuridine ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the oral combination of decitabine/cedazuridine tablets with venetoclax for certain adults ...

AI success depends on whether enterprise data is ready, reachable, and close enough to the workloads that need it. In this eSpeaks episode, Dell Technologies’ Vrashank Jain explains why fragmented ...

ORLANDO, Fla. — A new analysis of three decades of clinical trial data confirms that Black patients with acute myeloid leukemia (AML) have worse survival outcomes than White patients. However, ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...